The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
123755432 12375543 2 F 20160422 20160826 20160517 20160902 EXP FR-PFIZER INC-2016252684 PFIZER 60.00 YR F Y 0.00000 20160902 OT FR FR

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
123755432 12375543 1 PS TAHOR ATORVASTATIN CALCIUM 1 Oral 10 MG, DAILY Y 20702 10 MG FILM-COATED TABLET
123755432 12375543 2 SS COLCHIMAX (FRANCE) COLCHICINEOPIUM, POWDEREDTIEMONIUM 1 Oral UNK Y 0 FILM-COATED TABLET
123755432 12375543 3 SS COLCHIMAX (FRANCE) COLCHICINEOPIUM, POWDEREDTIEMONIUM 1 0.5 MG, DAILY Y 0 .5 MG FILM-COATED TABLET
123755432 12375543 4 SS ZYLORIC ALLOPURINOL 1 100 MG, DAILY Y 0 100 MG
123755432 12375543 5 SS ZYLORIC ALLOPURINOL 1 UNK Y 0
123755432 12375543 6 C KARDEGIC ASPIRIN LYSINE 1 160 MG, DAILY 0 160 MG
123755432 12375543 7 C CYMBALTA DULOXETINE HYDROCHLORIDE 1 60 MG, DAILY 0 60 MG
123755432 12375543 8 C COAPROVEL HYDROCHLOROTHIAZIDEIRBESARTAN 1 1 DF (DOSAGE FORM), DAILY 0 1 DF
123755432 12375543 9 C TEMERIT NEBIVOLOL 1 2.5 MG, DAILY 0 2.5 MG
123755432 12375543 10 C INEXIUM ESOMEPRAZOLE 1 20 MG, DAILY 0 20 MG
123755432 12375543 11 C DAFALGAN ACETAMINOPHEN 1 UNK, AS NEEDED 0
123755432 12375543 12 C METFORMIN METFORMIN HYDROCHLORIDE 1 500 MG, 2X/DAY (TWICE DAILY) 0 500 MG BID
123755432 12375543 13 C GALVUS VILDAGLIPTIN 1 50 MG, DAILY 0 50 MG
123755432 12375543 14 C LANTUS INSULIN GLARGINE 1 20 IU, 1X/DAY (THE EVENING) 0 20 IU QD
123755432 12375543 15 C APIDRA INSULIN GLULISINE 1 9 IU IN THE MORNING, 8 IU AT MIDDAY AND 12 IU IN THE EVENING 0 29 IU

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
123755432 12375543 1 Hypercholesterolaemia
123755432 12375543 2 Gout
123755432 12375543 4 Gout
123755432 12375543 12 Type 2 diabetes mellitus
123755432 12375543 13 Type 2 diabetes mellitus
123755432 12375543 14 Type 2 diabetes mellitus
123755432 12375543 15 Type 2 diabetes mellitus

Outcome of event

Event ID CASEID OUTC COD
123755432 12375543 HO
123755432 12375543 OT

Reactions reported

Event ID CASEID DRUG REC ACT PT
123755432 12375543 Acute prerenal failure
123755432 12375543 Cell death
123755432 12375543 Cholestasis
123755432 12375543 Rhabdomyolysis

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

Event ID CASEID DSG DRUG SEQ START DT END DT DUR DUR COD
123755432 12375543 1 20160423 0
123755432 12375543 2 20160307 20160422 0
123755432 12375543 4 20160307 20160423 0
123755432 12375543 12 201603 20160425 0
123755432 12375543 13 201603 20160425 0
123755432 12375543 14 201603 0
123755432 12375543 15 201603 0